GHENT, BELGIUM--(Marketwire - April 27, 2012) - REGULATED INFORMATION
GHENT, Belgium, 27 April 2012 - Ablynx (EURONEXT BRUSSELS: ABLX)
today
announced, in accordance with Article 14 of the Belgian Law of 2 May
2007
regarding the publication of major shareholdings in issuers whose
securities are
admitted to trading on a regulated market (the "Transparency Law"),
that it
received a notification of shareholdings from vzw VIB.
The above shareholder now owns less than 3% in Ablynx.
Full versions of all transparency notifications are available on the
website of
Ablynx, section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and
development
of Nanobodies(®), a novel class of therapeutic proteins based on
single-domain
antibody fragments, for a range of serious and life-threatening human
diseases,
including inflammation, haematology, oncology and pulmonary disease.
Today, the
Company has over 25 programmes in the pipeline and seven Nanobodies at
clinical
development stage. Ablynx has ongoing research collaborations and
significant
partnerships with major pharmaceutical companies, including
Boehringer
Ingelheim, Merck Serono and Novartis. The Company is headquartered in
Ghent,
Belgium. More information can be found on www.ablynx.com.
Complete version of the press release:
http://hugin.info/137912/R/1607016/509633.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1607016]
